We have been performing a clinical study using CMX-001, a lipid-conjugated form of cidofovir, which has excellent oral bioavailability and lacks the kidney toxicity of cidofovir, in patients with severe herpes simplex, cytomegalovirus, and adenovirus infections. In addition to using CMX-001 for these diseases, we also treated an immunocompromised patient who had disseminated molluscum contagiosum virus (MCV) disease and severe human papillomavirus with CMX-001. While the patient had to stop the medication due to toxicity, we found that she had MCV DNA in 20% of blood samples while on therapy, compared with MCV DNA in 50% of blood samples while off of therapy. We noted improvement of her human papillomavirus infection of her fingers while on CMX-001. This study suggests that CMX-001 may be beneficial in immunocompromised patients with certain severe virus infections. We have also been searching for new viruses in persons with unexplained diseases. We studied cohorts of patients with chronic fatigue syndrome and chronic inflammatory diseases of unknown etiology (including rheumatoid arthritis, Behcets disease, systemic lupus erythematosis, dermatomyositis, polymyositis, and scleroderma) for evidence of xenotropic murine leukemia virus-related virus (XMRV) and other murine leukemia virus-related viruses. Prior reports had shown an association of these viruses in patients with chronic fatigue syndrome. We failed to convincingly detect virus sequences in patients with chronic fatigue syndrome, chronic inflammatory syndromes, or in blood bank donors. Serum from patients with chronic fatigue syndrome did not contain antibodies to XMRV. Thus, we did not detect evidence of XMRV infection in patients with chronic fatigue syndrome or in those with chronic inflammatory diseases whose cause is unknown.

Project Start
Project End
Budget Start
Budget End
Support Year
38
Fiscal Year
2012
Total Cost
$448,678
Indirect Cost
City
State
Country
Zip Code
Wang, Kening; Hoshino, Yo; Dowdell, Kennichi et al. (2017) Glutamine supplementation suppresses herpes simplex virus reactivation. J Clin Invest 127:2626-2630
Liu, XueQiao; Cohen, Jeffrey I (2016) Epstein-Barr Virus (EBV) Tegument Protein BGLF2 Promotes EBV Reactivation through Activation of the p38 Mitogen-Activated Protein Kinase. J Virol 90:1129-38
Dropulic, Lesia K; Ali, Mir A; Ombrello, Amanda K et al. (2016) Periodic Illness Associated With Epstein-Barr Virus: A New Diagnosis After a 22-Year Follow-up. Clin Infect Dis 62:1613-4
Li, Qingxue; Wilkie, Adrian R; Weller, Melodie et al. (2015) THY-1 Cell Surface Antigen (CD90) Has an Important Role in the Initial Stage of Human Cytomegalovirus Infection. PLoS Pathog 11:e1004999
Cohen, Jeffrey I (2015) Primary Immunodeficiencies Associated with EBV Disease. Curr Top Microbiol Immunol 390:241-65
Lamers, Susanna L; Newman, Ruchi M; Laeyendecker, Oliver et al. (2015) Global Diversity within and between Human Herpesvirus 1 and 2 Glycoproteins. J Virol 89:8206-18
Liu, XueQiao; Cohen, Jeffrey I (2015) The role of PI3K/Akt in human herpesvirus infection: From the bench to the bedside. Virology 479-480:568-77
Bayat, Ahmad; Burbelo, Peter D; Browne, Sarah K et al. (2015) Anti-cytokine autoantibodies in postherpetic neuralgia. J Transl Med 13:333
Newman, Ruchi M; Lamers, Susanna L; Weiner, Brian et al. (2015) Genome Sequencing and Analysis of Geographically Diverse Clinical Isolates of Herpes Simplex Virus 2. J Virol 89:8219-32
Schulz, Katharina S; Liu, Xueqiao; Klupp, Barbara G et al. (2014) Pseudorabies virus pUL46 induces activation of ERK1/2 and regulates herpesvirus-induced nuclear envelope breakdown. J Virol 88:6003-11

Showing the most recent 10 out of 24 publications